Marksans Pharma Limited

rs,

Date: May 19, 2025 BSE Limited Corporate Relation Department Phiroze Jeejeebhoi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404 National Stock Exchange of India Limited List

35%

tnessed strong performance across all our markets, the US market has been a key growth driver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing INR 2000 Crs

INR 2000

iver with 35% YoY increase in revenue. Our OTC segment’s performance is at all-time high, crossing INR 2000 Crs in revenue, a testament to our focus and execution on expanding the OTC product pipeline. Looki

₹ 2,623

ars.” Mark Saldanha M A N A G I N G D I R E C TO R A N D C E O FY25 Q4 FY25 Operating Revenue ₹ 2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529

20.5%

Saldanha M A N A G I N G D I R E C TO R A N D C E O FY25 Q4 FY25 Operating Revenue ₹ 2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3

₹ 560.0

I N G D I R E C TO R A N D C E O FY25 Q4 FY25 Operating Revenue ₹ 2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr

15.2%

E C TO R A N D C E O FY25 Q4 FY25 Operating Revenue ₹ 2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr +14.7% Y

₹ 708

FY25 Operating Revenue ₹ 2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr +14.7% YoY EBITDA EBITDA Margin 20.2

26.5%

rating Revenue ₹ 2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr +14.7% YoY EBITDA EBITDA Margin 20.2 % -91 bps

₹ 529

2,623 cr +20.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr +14.7% YoY EBITDA EBITDA Margin 20.2 % -91 bps YoY ₹ 109.6 cr +

15.3%

0.5% YoY Revenue ₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr +14.7% YoY EBITDA EBITDA Margin 20.2 % -91 bps YoY ₹ 109.6 cr +0.1% YoY

₹ 126

₹ 560.0 cr +15.2% YoY Operating Revenue ₹ 708 cr +26.5% YoY EBITDA ₹ 529 cr +15.3% YoY EBITDA ₹ 126 cr +14.7% YoY EBITDA EBITDA Margin 20.2 % -91 bps YoY ₹ 109.6 cr +0.1% YoY EBITDA Margin 17.8%

“Unit 2 in Goa Acquired Manufacturing facility in Goa • Scalable capacity with a plan to double the existing Indian capacity from 8bn units per annum • Manufacturing site is spread across 47,597 sq.”

“• Plan to manufacture tablets, ointments, liquids and creams AC C R E D I TAT I O N S *Acquired facility in Goa has scalable capacity to 8bn units p.a.”

“• Our OTC segment grew at CAGR of 21% (from FY17-FY25).”

“Majority of revenue in OTC comes from manufacturing and selling store brands for key retailers in key regions • Marksans is the most preferred and growing low-cost store brand manufacturing partner Capacity expansion • • Aim to scale the acquired unit in Goa, capacity to 8bn units p.a.”

“₹ 207 cr in FY25 Disciplined capital allocation Strong credit rating • India rating : IND AA- / Stable Low financial risk Driving inorganic growth.”

“Evaluating acquisitions in Europe region for front-end presence 35 We’ve Delivered What We Promised Marksans Guidance How have we performed?”

“Revenue guidance of ₹ 2,000 cr EBITDA margin guidance of 20% Focus on expanding OTC business – ~4.6x revenue growth since 2017 Disciplined capital allocation approach - Effectively utilizing the cash through buyback, dividends, targeted acquisitions and capacity expansion Achieved Achieved Achieved Achieved 36 Growth: FY25 and Beyond Disciplined efforts to become future ready Growth FY25 and Beyond • Doubling low-cost manufacturing capacity in India from 8bn to 16bn units.”

Total Capacity

1

For more information please contact

1

Total Capacity

26 bn units p.a.* USA INDIA Manufacturing Facility in Southport, UK • Manufactures non-sterile liquids, ointments and powder sachets UK • Supplies to UK, West Africa & Middle East • Spread across 7,300 sq. mt. C A PAC I T Y 2 bn bottles p.a. 1 bn tubes p.a. 1 bn sachets p.a. AC C R E D I TAT I O N S Manufacturing Facility in Farmingdale, USA • Manufactures hard gels, tablets and capsules • Spread over an area of 7000 sq. mt. • "Made in the USA” product offering • Added incremental packaging lines CAPACITY ACCRE DI TAT I O NS 6 bn tablets and hard capsules p.a. Unit 1 in Goa Existing Manufacturing facility in Goa • Manufactures Capsules & Tablets • One of the biggest manufacturing facilities in Asia • Fully-automated unit spread over 18,000 sq. mt. campus • Generic pharmaceuticals manufactured from this facility are exported across the globe ACCRE DI TAT I O NS CAPACITY 2.4 bn softgel and hard gelatin capsules p.a. 6 bn solid tablets p.a. Unit 2 in Goa Acquired Manufacturing facility in

For more information please contact

Jitendra Sharma (CFO) Marksans Pharma Ltd. Tel: +91 22 4001-2000 jitendra@marksanspharma.com Corporate Office 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2025 Marksans Pharma Ltd., All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.